“Pfizer and EU Negotiate Reduction in Covid-19 Vaccines Purchase, Spain and Other Countries May Pay Half Price”

Pfizer and the European Union They are in the middle of negotiating reduce the number of vaccinations Covid-19 purchased by member states. The latest proposal from the pharmaceutical company is that Spain and the rest of the EU countries pay half the price, about 10 eurosfor each of the nearly 70 million canceled doses, as reported Financial Times y Reuters. Therefore they would be 700,000 million which would have to be paid.

The revised contract would allow the EU to catch up to newer adapted vaccines to any future variant of Covid-19, say sources close to the negotiation. However, not all countries would be in favor of this deal, since they do not want to pay for the canceled doses, as reported Financial Times. If the review proceeds, this would enhance the “almost monopoly” which these two companies (Pfizer and Biontech) enjoy in relation to the distribution of vaccines against Covid-19, as analyzed by the English newspaper.

At the beginning of this year, the existence of talks between the EU and the two drug manufacturers with the aim of reducing up to 500 million doses of the coronavirus vaccine that Brussels promised to buy this year in exchange for a higher price.

Vaccine Reserve Stock

In the case of Spain, Health explained to the communities autonomous the situation of renegotiation and sources close to the Ministry assured that “all countries by contract acquired a much higher volume of vaccines to those who are going to need” and they hope to reach an agreement soon. However, the volume of acquisition of these inoculations must take into account the need to keep “a reserve stock”.

Besides, Medical Writing asked Pfizer a few days ago about this matter and the company stated that the talks were taking place “willingly agree by both parties” and remained confidential. Although from Pfizer, and in line with what was expressed by the ministerial sources, they affirmed that they were “committed to find useful solutions to address the public health and evolving need and pandemic situation, while ensuring that Pfizer and Biontech continue to meet all of their contractual obligations relating to the Covid-19 vaccine delivery to the European Union”.